Opportunities and challenges for TCR mimic antibodies in cancer therapy

about

A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

P2860

Q38719407-00209F18-0D95-45BC-A1DE-408CC6454930 Q38920996-D2F5743B-4B56-4859-AEAF-6B87AF822550 Q47335259-CD3413A0-EC2B-4853-B972-4FE67708A8CA

P2860

Opportunities and challenges for TCR mimic antibodies in cancer therapy

Item

http://www.wikidata.org/entity/Q38812269

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Opportunities and challenges for TCR mimic antibodies in cancer therapy

@en

type

Item

label

Opportunities and challenges for TCR mimic antibodies in cancer therapy

@en

prefLabel

Opportunities and challenges for TCR mimic antibodies in cancer therapy

@en

P1476

Opportunities and challenges for TCR mimic antibodies in cancer therapy

@en

P2093

Aaron Y Chang

http://www.w3.org/2001/XMLSchema#string

Claire Y Oh

http://www.w3.org/2001/XMLSchema#string

David A Scheinberg

http://www.w3.org/2001/XMLSchema#string

Dmitry Pankov

http://www.w3.org/2001/XMLSchema#string

Emily Casey

http://www.w3.org/2001/XMLSchema#string

Tao Dao

http://www.w3.org/2001/XMLSchema#string

P2860

The Cancer Genome Atlas Pan-Cancer analysis project

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation

Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.

Complement is activated by IgG hexamers assembled at the cell surface.

Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol.

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.

Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias

P304

979-987

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2016.1176138

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ron S Gejman

Melissa D Mathias

Elliott J Brea

P577

2016-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27094818

http://www.w3.org/2001/XMLSchema#string

P932

4936943

http://www.w3.org/2001/XMLSchema#string

Opportunities and challenges for TCR mimic antibodies in cancer therapy

about

P2860

P2860

Opportunities and challenges for TCR mimic antibodies in cancer therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932